Sweden set to grant special permission for new drug to treat COVID-19 - (Xinhua via NewsPoints Desk)

  • The Swedish Medical Products Agency has authorised the emergency use of Eli Lilly's bamlanivimab in COVID-19 patients with underlying conditions that make them more vulnerable to the virus, as reported Xinhua on Thursday.

  • The drug is currently under review by the European Medicines Agency.

  • "It is in the approval process and as the results look promising, we believe that we can take advantage of this drug in a controlled way," said Charlotta Bergquist, group manager of efficacy and safety at the Swedish Medical Products Agency.

  • "Treatment should be started early in the course of the disease for those who risk becoming seriously ill," she added.

To read more NewsPoints articles, click here.